Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Maravai Lifesciences Holdings (MRVI) Accumulated Depreciation & Amortization (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 5 years of Accumulated Depreciation & Amortization data on record, last reported at -$160.6 million in Q4 2024.

  • For Q4 2024, Accumulated Depreciation & Amortization fell 40.75% year-over-year to -$160.6 million; the TTM value through Dec 2024 reached -$160.6 million, down 40.75%, while the annual FY2024 figure was -$160.6 million, 40.75% down from the prior year.
  • Accumulated Depreciation & Amortization reached -$160.6 million in Q4 2024 per MRVI's latest filing, down from -$114.1 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at -$32.6 million in Q4 2022 and bottomed at -$160.6 million in Q4 2024.
  • Average Accumulated Depreciation & Amortization over 5 years is -$89.3 million, with a median of -$99.7 million recorded in 2020.
  • Peak YoY movement for Accumulated Depreciation & Amortization: surged 60.46% in 2021, then crashed 250.03% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at -$99.7 million in 2020, then soared by 60.46% to -$39.4 million in 2021, then grew by 17.28% to -$32.6 million in 2022, then plummeted by 250.03% to -$114.1 million in 2023, then crashed by 40.75% to -$160.6 million in 2024.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were -$160.6 million in Q4 2024, -$114.1 million in Q4 2023, and -$32.6 million in Q4 2022.